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Chapter 1: Introduction
Influenza:
As this recent pandemic has shown us, circulating viruses, when given the right
conditions, can mutate into an entirely new virus capable of posing a serious global health
threat1. Influenza, like Covid-19, is a respiratory disease caused by an RNA virus that can be
transmitted to us from humans or animals2. The GLaMOR Project estimates the annual global
influenza-associated respiratory deaths at nearly 400,000 each year (294,000 - 518,000), 67% of
which occur in people aged 65 years and older3. The elderly in the United States bear the
greatest burden of influenza-related respiratory death (75%) and are more than 26 times likely
to die as a result of influenza infection compared to the general population3.
Influenza A and B viruses, belonging to the family Orthomyxoviridae, are causes of
seasonal epidemics and occasionally pandemics (influenza A) of respiratory diseases4. Influenza
viruses, depicted in Figure 1, are negative sense single-stranded RNA enveloped viruses with a
segmented genome that encodes RNA polymerase, viral glycoproteins that are expressed on
the viral envelope surface and various matrix, membrane and nonstructural proteins 5. The
glycoproteins expressed on the viral envelope are of critical importance due to their role in
facilitating viral entry and release in host cells and they are the targets of neutralizing
antibodies produced in response to influenza infection or vaccination6. Additionally, these
surface proteins determine the antigen subtype of the influenza virus, i.e. influenza viruses are
named depending on what subtype of hemagglutinin (HA) and neuraminidase (NA) proteins it
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possesses4. The most common influenza A virus strains that infect humans are avian H3N2 and
swine H1N1 strains7.
Based on the phylogeny of influenza HA proteins they can be divided into 2 groups and 4
clades, meaning the HA proteins within a clade or group are genetically similar 7. These
relationships are genetically conserved and localized in the ‘stalk’ region of the HA protein. The
globular ‘head’ is where the antigenic diversity and specificity is located, as well as being the
targets of neutralizing antibodies induced by seasonal influenza vaccination 8.
Once an influenza viral particle successfully enters the host cell (Figure 1) viral
replication occurs and the virus is packaged and released while simultaneously and
unintentionally alerting the immune system and initiating an anti-viral immune response7.
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Figure 1. Influenza virus particle, classification, and replication.
A) Influenza viruses is a ssRNA virus that encodes multiple viral proteins, is encased in a lipid envelope
and expresses HA and NA on the viral surface. B) Classification of influenza subtypes are based on which
HA and NA proteins the influenza virus express. Subtypes of HA are arranged via genetic similarities via a
maximum likelihood phylogenetic tree.
C) Surface proteins are antigenically diverse and facilitate (HA) influenza virus binding and entry into
host cells. Once the influenza virus escapes from the endosome, viral replication occurs, followed by
viral packaging and escape as well as triggering an IFN-mediated antiviral immune response and cell
apoptosis. (Medina & Garcia-Sastre 2011)7
3

Influenza A viruses have high mutation rates which lead to antigenic drift, an
accumulation of genetic mutations over time that alters the antigen of the virus to allow the
virus to evade the immune system and cause reinfection, leading to annual influenza
epidemics9. These high mutation rates also increase the likelihood of antigenic shift
(concomitant influenza infections that lead to genetic reassortment) which generates an
entirely novel influenza virus4.
The genetic diversity of influenza viruses is largely due to circulation in animal reservoirs
such as hundreds of species of wild migratory birds, poultry, pigs, bats, and horses, which
increases the antigen diversity and contributes to high mutation rates of influenza10. Novel
viruses have an increased potential for high morbidity and mortality, as opposed to the typical
seasonal influenza viruses that ordinarily produce severe disease and death only in high risk
populations, such as the elderly (65+ years), immunocompromised individuals, those with
underlying health conditions, those without adequate access to healthcare, and pregnant
persons3,11,12.

Influenza Infection:
Influenza is a viral respiratory disease with symptoms ranging from upper respiratory
tract symptoms such as runny nose, cough, joint and muscle pain, fatigue, fever, chills, to
severe cases of pneumonia caused by either influenza in the lower respiratory tract or
secondary bacterial infection, which can lead to severe illness and death5,13. Influenza infections
in those with underlying health conditions can lead to exacerbation of disease and instances of
death or chronic illness due to heart and other organ complications14.
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During natural influenza infection, the ssRNA of the influenza virus is recognized by an
endosomal TLR7/8 in the infected respiratory epithelial cell, initiating a signal cascade via the
adaptor protein myeloid differentiation factor 88 (MyD88) to alert the immune system 15. Once
the signaling cascade is activated there is a release of pro-inflammatory cytokines (TNFα and IL6) and type I interferons (IFNα and IFNβ) which attract local innate immune cells to the area,
cells such as monocytes, neutrophils, and various antigen presenting cells like dendritic cells
and macrophages16,17. Early and sustained activation of the innate immune system is key in
initiating an effective adaptive immune response.
As depicted in Figure 2, the innate immune system is the initial defense mounted and it
is followed by the adaptive immuntiy involved in influenza infection resolution; including the
humoral response with B cell antibody production (neutralizing antibodies) and cell mediated
immunity producing CD4+ helper T cells and CD8+ cytotoxic T cells18,19. This results in an
antiviral Th1 immune response culminating in B cell activation, antibody production, and T cell
recruitment and activation.
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Figure 2. Human Host Immune Response to Influenza A Infection.
A diagram of the different arms of the immune response that is activated in response to avian
influenza A infection. The innate immune response consists of respiratory epithelial cell
infection and innate immune cell activation that results in inflammatory cytokine release. The B
cell response results in HA head-specific antibody production and the T cell response
culminates in CD8+ cytotoxic T cell killing of infected cells.
(Adapted from Koutsakos et al. 2019)19
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Once the adaptive immune system is engaged, cell-mediated immunity, including both
CD4+ and CD8⁺ T cells are involved in infection resolution with CD4+ T cells supporting B cell
activation, antibody production (IgG, IgG2a, and 2IgG1), alveolar macrophage activation, CD8+ T
cell polarization (IFNγ), and Tfh cell activation16. CD8+ T cells are subsequently activated into
IFNγ producing, cytotoxic T cells that directly kill influenza infected cells18. Interestingly, CD8+ T
cells are identified as the cell type critical to influenza cross-protection of multiple influenza
strains and subtypes20, highlighting the importance of an influenza vaccine that provokes a T
cell response.

Influenza Vaccines:
Current seasonal influenza vaccines are effective at inducing strain specific antibodies
that are specific to the subtype of surface proteins on the influenza virus, namely HA and NA21.
These strain specific antibodies fail to protect against heterologous (influenza viruses with
similar but genetically distinct) HA and NA proteins) or heterosubtypic (influenza viruses with
different HA and NA proteins) infection, thus requiring seasonal vaccination22. A promising
solution to inducing broader and enhanced protection are adjuvants. However, even with
ranging vaccine effectiveness, vaccination remains the most effective way to prevent influenza
related hospitalizations and death23–25.
The standard seasonal influenza vaccine, recommended for most US adults without
underlying health conditions, during the 2021-2022 influenza season is a quadrivalent
inactivated non-adjuvanted vaccine that includes HAs from 2 influenza B strains and two
influenza A strains, H1N1 and an H3N226. The two inactivated quadrivalent vaccines for the
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elderly utilize different techniques to increase immunogenicity – a high-dose non adjuvanted
vaccine (higher dose of antigen) and a standard MF59 adjuvanted vaccine 26. Adjuvants and
novel vaccine strategies have already proven more effective at preventing hospitalization and
death in the elderly, the next step is refining adjuvants for a more targeted and specific immune
response27–29.

Adjuvants:
Adjuvants are compounds included in vaccines to bolster the antigen specific immune
response induced by vaccination and have been safely used in vaccines for decades 30,31.
Current seasonal influenza vaccines, 2021-2022 influenza season, do not contain adjuvants,
however a vaccine for high risk populations and pandemic preparedness contain adjuvants 32.
The only approved adjuvant for use in an influenza vaccine is MF59 – an oil-in-water
emulsion28,31. Importantly, these adjuvanted influenza vaccines have demonstrated better
protection in vulnerable populations such as the elderly, the immunocompromised and those
with underlying health conditions24,27,28,33.
Current approved vaccines in the US include adjuvants such as Aluminum, MF59, AS04,
AS01, CpG ODN31,32,34. Of particular interest are adjuvants that activate cell mediated immunity,
which is essential in influenza infection resolution35,36. Agonists that activate pattern
recognition receptors (PPRs) have been proven to be effective adjuvants at activating the
adaptive immune system37,38. Toll-like receptors (TLRs), a family of pattern recognition
receptors (PRRs) that recognize pathogen associated molecular patterns (PAMPs) found in
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infectious agents such as viruses and bacteria, have demonstrated enhanced influenza vaccine
adjuvant activity39,40. Adjuvants derived from bacterial PAMPs, such as AS04, AS01, and CpG
ODN, activate TLRs on innate immune cells, which is essential for a protective adaptive
response, and have demonstrated enhanced protection and safety41–44. Recent studies indicate
the promise of TLR agonists as adjuvants in influenza vaccines, particularly combinations of TLR
agonists have shown to enhance influenza vaccine effectiveness45,46

Toll-like Receptors:
The prototype PRR are toll-like receptors (TLRs) and they are critical in initiating an
adaptive immune response. TLRs are expressed on multiple cell types but specifically on innate
immune cells such as macrophages and dendritic cells, as well as non-immune cells like
fibroblasts and epithelial cells47. TLRs, as depicted in Figure 3, are expressed on the cell surface
and in the endosome and signal through either Toll-interleukin receptor (TIR)-domaincontaining adapter-inducing interferon-β (TRIF) or myeloid differentiation primary-response
protein 88 (MyD88)47,48. Interestingly, TLR4 is the only TLR that uses both MyD88 and TRIF
signaling pathways, all other TLRs use either MyD88 or TRIF49. TRIF signaling has been shown to
result in the production of Th1 cytokines such as IL-2 and IFNγ, important for influenza
resolution and the clonal expansion of T cells, which are critical for influenza cross-protection49–
51.

MyD88 signaling is involved in TLR2, 4, 5, 7, 8, and 9 activation and is associated with a pro-

inflammatory immune response and type 1 IFN production48.
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Figure 3. Toll-Like Receptors signaling pathway in Innate Immune Cells.
TLRs 1, 2,4, 5, 6, are expressed on the cell surface of innate immune cells, while TLRs 3,7,8, and
9 are expressed in the endosome. Uniquely TRL4 is expressed on the cell surface and
intracellularly. All TLRs except for intracellular TLR4 and TLR 3 signal through MyD88, TLR3 and
intracellular TLR4 signal through TRIF. TLR activation and signaling involve adaptor proteins and
result in transcription of pro-inflammatory cytokines and Type I IFNs. (Duan et al. 2022)47

The combination of a TLR4 adjuvant, shown to broaden influenza protection 52 by
induction of IFNγ response via TRIF signaling53, and TLR7/8 agonist, which induces an antiviral
immune response through MyD8854, could lead to a unique immune response that enhances T
cell mediated immunity55. Thus, using agonists that slightly modulate the immune response by
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activating related but distinct signaling pathways, and inducing a Th1 bias could lead to
improved influenza protection.

Scope of Thesis:
Our lab has reported on several synthetic TLR agonists, oxoadenines and
imidazoquinolines, derived from natural PAMPs that bind human TLR ligands and have
demonstrated heterologous protection when used as an adjuvant in an influenza vaccine 56,57.
Here we further examine our lead lipidated oxoadenine adjuvant, INI-4001, and the influenza
challenge model development that was undertaken to evaluate the influenza protection
achieved using INI-4001, alone and in combination with TLR4 agonist CRX-601, in liposome
formulations.
The TLR7/8 agonists chosen for this study are UM-3002, an RNA mimetic, and INI-4001
which is UM-3002 with a lipid tail. The TLR4 agonist chosen for this study is CRX-601, which our
lab has previously used to enhance influenza vaccination, and it’s recently been evaluated in a
Phase I clinical trial for oncology58, demonstrating effectiveness and safety. CRX-601 was
chosen as our TLR4 agonist, as we have previously shown enhanced influenza protection as a
vaccine adjuvant, it’s similar to current approved TLR4 adjuvants, and is currently in human
clinical trials56,59,58,60. TLR agonists are already used in approved vaccines, further demonstrating
their safety and efficacy in vaccine settings, increasing the probability that TLR adjuvants in an
influenza vaccine would produce a safe and protective vaccine, without increasing side
effects34,42,61.
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We hypothesize that targeted co-delivery of our combined adjuvants to APCs in a single
liposome will lead to dual activation of a single cell to boost the Th1 bias and produce more
effective and unique T cell and antibody responses. Encapsulating our TLR ligands inside a
liposome allows for better control of the delivery of adjuvants and antigen, targets the cellular
compartment where TLR7/8 signaling occurs, and avoids the toxicity associated with systemic
TLR agonists62.

Chapter 2: Influenza Mouse Adaptation and Challenge Model Development
Mouse adaptation of A/California/07/2009 influenza A virus:
In order to evaluate the protection achieved with INI-4001 and CRX-601 adjuvants in an
influenza vaccine we chose to use two subtypically different influenza viruses in our challenges.
The influenza strain vaccinated with is detergent-split A/Victoria/3/75(H3N2) (A/Vic) influenza.
A/Vic was chosen as it’s already licensed for use in influenza vaccines and we wanted see if we
would see enhanced protection with the addition of an adjuvant. A genetically drifted H3N2
was chosen, A/Hong Kong/1/68 (H3N2), as our lab has previously mouse adapted and
developed an influenza challenge model with it and because of similar subtype to the virus used
as an antigen in the vaccine. The next virus was chosen because of its relevance to human
health and because it contains different NA and HA proteins than the previously mentioned
influenza strains. A mouse-adapted H1N1 influenza virus, A/California/07/2009, was chosen to
investigate heterosubtypic protection. In essence, the HK68 challenge will determine if
protection is seen from genetically drifted H3N2 influenza infection, i.e. the same HA and NA
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proteins, and the maA/Cal (H1N1) challenge will evaluate protection against influenza viruses
with different envelope proteins (heterosubtypic protection). The A/California strain was also
chosen because of it’s relevance to human health as H1N1 is a common historical cause of
influenza pandemics, both in recent history, the 2010 Swine flu pandemic63, and the previous
century (1918 Spanish Flu)64.
However, we didn’t have a mouse adapted H1N1 influenza virus. Before assuming the
egg passaged A/California H1N1 virus in storage needed to be mouse adapted, it was checked
for lethality in BALB/c mice, data shown in Figure 4. The most weight loss observed was 20%. As
30% weight loss is considered lethal, the egg passaged virus is not lethal in mice.

% Weight Loss after A/California (H1N1) Challenge
0
Day 1 Day2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10Day 11Day 12Day 13
-5
-10
-15
-20
-25
10uL NEAT

15 uL NEAT

1:05

1:25

Figure 4. A/California H1N1 is not lethal in BALB/c mice. Naïve BALB/c mice were inoculated
intranasally (10 µL/nare) with different dilutions of virus to determine an LD 50. Body
temperature, weight, and clinical scores were assessed daily. Percent body weight loss graph of
mice challenged with 3LD50 HK68 are shown, n = 5.
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Thus, it was necessary to increase lethality for future use of the virus in a murine
influenza challenge model. A/California/07/2009 influenza virus was mouse adapted using a
protocol previously described65. Briefly, naive BALB/c mice were infected with egg passaged
A/Cal intranasally, 10 µl/nare. Lungs were harvested on day 3, homogenized, and supernatant
was collected and ultracentrifuged with a sucrose cushion, concentrating the influenza
particles. The next batch of mice was infected with the ultracentrifuged virus, and the process
was repeated. This was completed for a total of 10 passages. After the final passage the newly
mouse adapted virus was tested for lethality. As Figure 5 demonstrates, the mouse adapted
A/California/07/2009 (maA/Cal) influenza virus is lethal in BALB/c mice.
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% Weight Loss Mean +/- SEM

Percent Weight Loss post infection of H1N1 A/California

A

NEAT

0

1:2
1:4
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1:16
1:8
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Days Post Challenge

maA/Cal LD50 Envigo
B

100

% Survival

80

NEAT
1:2
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1:4
40

1:8

20

1:16

0
4
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Days Post Challenge

Figure 5. Mouse adapted A/California H1N1 influenza virus is lethal in BALB/c mice and has a
preliminary LD50 of 1:12 dilution. Naïve BALB/c mice were inoculated intranasally (10 µL/nare)
with different dilutions of virus to determine an LD50 dose. Body temperature, weight, and
clinical scores were assessed daily. Percent Weight loss and survival graph of mice challenged
with serial dilutions of influenza subtype A/California (H1N1) are displayed (n=8). Mice were
observed twice daily and clinical body scores, temperatures, and weights were recorded daily for
each mouse. Criteria for euthanasia endpoints were: 1) 30% weight loss, or 2) body
temperature less than 23°C, or 3) body temperature less than 25°C two days in a row, or 4)
clinical body score of 4.

The next step was to determine the LD50 of maA/Cal in order to calculate the optimal
dose for future influenza challenge studies (results shown in Figure 5). As the virus was
previously non-lethal, a large LD50 was not expected, therefore small serial dilutions were used
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(1:2). According to the survival data (Fig 5B), only the group with 1:16 diluted virus survived
(100% survival) maA/Cal H1N1 challenge and the mice at the next dilution, 1:8, all died. This
indicates that the newly mouse adapted A/California influenza strain is lethal and has a
calculated preliminary LD50 of 1:12 and is ready to use in a murine influenza challenge model.

Mouse adapted A/Cal LD50 determination:
After the initial mouse adaptation of maA/Cal H1N1 and preliminary LD50 study, we
encountered a considerable problem in our influenza challenge model that required months of
further investigation. The results of this investigation, discussed in the next section, resulted in
the need to retest and confirm the LD50 of the maA/Cal strain in mice obtained from Jackson
laboratory before influenza challenge for vaccination studies. Figure 6 demonstrates exactly
why this ‘LD50 test’ was necessary as the previous LD50, found at a viral dilution of 1:12, is 100%
lethal in BALB/c ordered from Jackson labs (a different source than the preliminary LD 50 study).
The viral dilution of 1:12 should have produced 50% survival, but in mice ordered from Jax
there was 20% survival. This indicated the need for further LD50 studies using mice ordered
from Jackson laboratory at higher viral dilutions.
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maA/Cal LD50 JAX
100
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1:6

% Survival

80
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60
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Figure 6. Previous maA/California LD50 in BALB/c Envigo mice, is 100% lethal in Jackson
ordered mice. Naïve BALB/c mice ordered from Jax were inoculated with 10 µL/nare maA/Cal.
Groups correspond to the dilution of maA/California influenza virus used for infection.
Temperature, weight, and clinical scores were assessed daily. Survival graph of influenza
challenge is shown (n=8). Mice were observed twice daily and clinical body scores,
temperatures, and weights were recorded daily for each mouse. Criteria for euthanasia
endpoints were: 1) 30% weight loss, or 2) body temperature less than 23°C, or 3) body
temperature less than 25°C two days in a row, or 4) clinical body score of 4.

A Room Temperature (Room Temp) group was included to rule out time-dependent
temperature induced viral inactivation, i.e. whether long thaw times and careless handling
leads to viral inactivation and lack of lethality in mice. However, protocols dictate long thaw
times (30 – 60 mins) on ice and never allowed to get to room temperature. We tested this by
comparing different thaw methods of influenza virus. All other viral dilutions were thawed on
ice and kept it on ice. However, for the room temperature group the virus was thawed on the
lab bench at room temp for a half hour before influenza challenge of mice and not kept on ice.
It was later confirmed that influenza virus left out at room temp for an hour or more is still
lethal in mice. This data further supports the results of the next section, that the problems
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encountered in the influenza challenge model was likely due to the mice and not the influenza
virus.
Since the previous maA/Cal LD50 was a 1:12 dilution, and a drastic difference of LD50 in
the Jax mice was unexpected, viral dilutions from 1:12 to 1:324 were used to capture the
adjusted LD50. As Figure 7 shows, 1:324 is not a large enough dilution to calculate the LD50 of
maA/Cal in Jax mice. The largest dilution of maA/California in Jax BALB/c mice was 10% fatal.
Another study with larger dilutions of virus was needed to accurately capture the LD 50.

A
100

100

80

80

% Survival

% Survival

maA/Cal LD50 Jax FINAL

B

Survival post maA/Cal Challenge

1:12

60

1:36
40

1:108
1:324

20

1:200

60

1:400
40

1:800
1:1600

20

1:3200
0

0
0

5
Days post challenge

10

0

5
10
15
Days Post Challenge

Figure 7. maA/Cal LD50 with extended dilutions, LD50 finally calculated. Naïve BALB/c mice
ordered from Jax were inoculated intranassally with 10 µL/nare of serially diluted (1:3)
maA/California to determine an LD50. Temperature, weight, and clinical scores were assessed
daily. Survival graphs of influenza challenged mice are shown (n=8). Mice were observed twice
daily and clinical body scores, temperatures, and weights were recorded daily for each mouse.
Criteria for euthanasia endpoints were: 1) 30% weight loss, or 2) body temperature less than
23°C, or 3) body temperature less than 25°C two days in a row, or 4) clinical body score of 4.
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An extended study (Fig 7B) with serially dilutions starting at 1:200 and ending at 1:3200
was able to get an accurate LD50. The highest dilution, 1:3200, achieved 80% survival in Jax mice
and the next dilution, 1:1600, produced 40% survival. The LD 50 of maA/California was
determined to be a viral dilution of 1:2260. Finally, maA/Cal can be used for a heterosubtypic
challenge to evaluate the protection induced by INI-4001 (TLR7/8) and CRX-601 (TLR4) in an
influenza vaccine.
As previously mentioned, we weren’t expecting to see such a drastic change in LD 50 data
between mice ordered from Jax and Envigo. The next section describes how the differences in
influenza responses depending on mouse vendor were discovered and investigated.

Influenza Challenge Model Development:
As previously mentioned our lab has historically worked with influenza challenge models
and maintains historical LD50 data of the influenza viruses used. Due to our familiarity with
HK68 challenge in TLR7/8 and TLR4 adjuvanted influenza vaccinated mice, we had expectations
based on historical and published data of what the influenza challenge survival data would look
like. However, our initial HK68 (H3N2) heterologous influenza challenge with INI-4001 (INI4001) and CRX-601 in liposome formulations, produced some confounding data, shown in
Figure 8.
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Figure 8. Adjuvants fail to protect against lethal influenza challenge, defying historical data.
BALB/c mice were immunized twice i.m. 14 days apart with either 0.15 (high) or 0.03 (low)
µg/mouse detergent-split monovalent A/Vic adjuvanted with liposomal TLR4 agonist CRX-601,
TLR7/8 agonist INI-4001, admixed CRX-601 + INI-4001, or co-encapsulated CRX-601:INI-4001.
On day 42 mice were challenged with 3LD50 of either HK68 (H3N2) or A/California (H1N1)
intranasal with 10 uL/nare. Mice were observed twice daily and clinical body scores,
temperatures, and weights were recorded daily for each mouse. Criteria for euthanasia
endpoints were: 1) 30% weight loss, or 2) body temperature less than 23°C, or 3) body
temperature less than 25°C two days in a row, or 4) clinical body score of 4. A) Survival graph
and B) % body weight loss graph of mice challenged with 3LD 50 HK68, mean and SEM are
displayed (n=10).
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The results of this first challenge study were inconclusive and inconsistent with previous
challenge studies performed in our laboratory (published and unpublished data). Previously, we
had seen complete protection from death with CRX-601 aqueous alone and better protection
(less weight loss) with TLR 7/8 agonists in combination with CRX-60157. Due to the multiple
variables in the experiment, there are multiple instances where mistakes could have occurred.
3 different possible causes of the difference in influenza protection from CRX-601 were
identified; 1. Formulation of CRX-601, 2. Antigen dose, and 3. Batch of HK68 influenza virus. The
historic CRX-601 data was obtained using the aqueous formulation of CRX-601 and this study is
concerned with liposome formulations. Perhaps the aqueous formulation, not the liposome,
are protective. The historical data referenced used a higher antigen dose of A/Vic than the
recent study, 0.3 µg compared to 0.15 µg. Additionally we sought to compare the recent batch
of HK68, tested in the previous study, to the older batch of HK68 that was used and published
with, where the CRX-601 adjuvanted influenza vaccine protected against lethal HK68 influenza
challenge.
In order to elucidate what happened, a repeat challenge was performed using two
different batches of HK68, an increase in antigen, and two formulations of CRX-601 (Figure 9).
From this data we can conclude there is a difference in weight loss (Fig 9B) and survival (Fig 9A)
between influenza batches (green/blue vs pink/purple groups). All the mice challenged with the
new batch of virus died, where previously protection was observed, and some of the mice
challenged with the new viral batch survived (20-60%). Additionally, it appears CRX-601
liposome and aqueous formulations demonstrate some protection and antigen dose appears
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irrelevant. However, the 100% survival previously seen with CRX-601 aqueous vaccinated mice
was still not achieved. Although there is a difference in survival and weight loss between
influenza strain batches, or lots, it isn’t enough to account for the altered performance of CRX601. This lead us to question the integrity of our breeding colony mice.
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Figure 9. Adjuvants produce partial protection, not correlating with previous studies. BALB/c
mice were immunized twice i.m. 14 days apart with either 0.15 or 0.3 µg/mouse detergent-split
monovalent A/Vic adjuvanted with either aqueous or liposomal TLR4 agonist CRX-601. On day
42 mice were challenged with 3LD50 of either recent HK68 (pink/purple) or old HK68 (H3N2)
influenza intranasal with 10 µL/nare. Mice were observed twice daily and clinical body scores,
temperatures, and weights were recorded daily for each mouse. Criteria for euthanasia
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endpoints were: 1) 30% weight loss, or 2) body temperature less than 23°C, or 3) body
temperature less than 25°C two days in a row, or 4) clinical body score of 4. A) Survival graph
and B) % body weight loss graph of mice challenged with 3LD 50 HK68. Mean and SEM are
displayed (n=8).

When mice were inoculated intranasally with influenza virus it was noted that mice
displayed nasal inflammation and discharge suggesting an underlying respiratory infection that
could be affecting the challenge study. If mice have an underlying respiratory infection when
challenged with 3 times the median lethal dose of influenza their immune systems would be
overtaxed and it could explain the lack of protection.
This led to further studies to establish if our breeding colony was immunocompromised.
This was done with a simplified influenza challenge study using different dilutions of the newer
batch of HK68 influenza virus and mice from different vendors to determine if our breeding
colony mice had underlying health issues. Myself and a colleague, Margaret Whitacre, worked
on this project. I am including some of her work (that I helped with) for context.
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Figure 10. Influenza protection varies depending on the vendor of BALB/c. Naïve BALB/c mice
obtained from either Jax or Envigo were challenged intranasally with 10 µL/nare of different
dilutions of HK68 influenza virus. Mice were observed twice daily and clinical body scores,
temperatures, and weights were recorded daily for each mouse.200420.LD50
Criteria for euthanasia
A/HK/68 YY 6/30
endpoints were: 1) 30% weight loss, or 2) body temperature less than 23°C, or 3) body
temperature less than 25°C two days in a row, or 4) clinical body score of 4. Survival graph of
mice challenged with the new batch of HK68 influenza virus (n=10). *Data obtained from
Margaret Whitacre.

Mice from two different vendors, Envigo, where our breeding colony mice are derived
from, and Jackson Laboratory (Jax) were challenged with three different dilutions of HK68.
Figure 10 demonstrates the difference in influenza challenge survival demonstrated by mice
from different vendors of BALB/c mice. As shown, influenza virus given at similar dilutions,
produce different lethality depending on where the mice were ordered from. In particular,
Envigo mice (red line with circle) challenged with a 1:2000 dilution virus had 100% mortality
compared to the same dilution in Jax mice (red line with diamond) with over 50% survival.
Envigo mice also failed to demonstrated a viral dose response. Envigo mice challenged with a
1:6000 (red line with square) and 1:18000 (red line with diamond) HK68 dilution resulted in
90% lethality. Note how Jax mice demonstrate a viral dose effect on the survivability of mice,
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i.e. Jax mice challenged with a 1:2000 HK68 dilution (black line with circle) had 70% survive, a
1:6000 dilution (black line with square) had 80% survive, and a 1:18000 dilution leads to 90%
survival. In other words, the larger the dilution of virus, the less virus challenged with, and the
more mice survive. Envigo mice failed to reproduce a viral dose response. This led us to ask
which vendor we should obtain our mice from for use in our influenza challenge model?
For this purpose, we included INI-4001 and CRX-601 adjuvants in an influenza vaccine
(i.n. or i.m.). The i.n. administration of agonists is for use in a non-specific resistance model. This
NSR model is to evaluate the influenza protection achieved from i.n. administering agonists and
challenging with influenza 48 hours later. Antigen is not including with these agonists as in an
i.m. vaccine, as the immune response achieved is non-specific and doesn’t require antigen. We
have historical data for adjuvants in both formulations and both models and wanted to see if
we could reproduce our historical data in either Jax or Envigo mice in order to determine which
vendor to order mice from for influenza challenges.
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Figure 11. Mice from Jackson Laboratories are consistent with previous data. BALB/c mice,
from either (A) Jackson laboratories or (B) Envigo were vaccinated either IN in a non-specific
resistance model where compounds are administered IN 48 hrs before influenza challenge, or
the standard IM influenza vaccine schedule with aqueous CRX-601 and blank liposomes and
then challenged IN (10 µl/nare) with 1:2000 HK68 influenza virus. Mice were observed twice
daily and clinical body scores, temperatures, and weights were recorded daily for each mouse.
Criteria for euthanasia endpoints were: 1) 30% weight loss, or 2) body temperature less than
23°C, or 3) body temperature less than 25°C two days in a row, or 4) clinical body score of 4.
Survival graph of mice challenged with HK68 influenza virus (n=10). *Data obtained from
Margaret Whitacre

In Figure 11, A) Jax and B) Envigo vaccinated mice were challenged with HK68 influenza
virus. Mice were vaccinated (i.m. or i.n.) with CRX-601 in both aqueous formulations. In Jax
mice (Fig 8A) CRX-601, i.m. and i.n., protect against lethal HK68 influenza challenge. Another
indication of a well-functioning influenza challenge model, the naïve group in the Jax mice had
no survival. Envigo influenza challenge data, on the right (Fig 8B), does not exhibit consistent
survival data. CRX-601 influenza protection, in Envigo mice (orange lines), changes depending
on vaccine route of administration. Previously CRX-601 i.n. demonstrated protection, however
in this experiment CRX-601 administered i.n. showed no protection against HK68 challenge,
inconsistent with historical data. Additionally, CRX-601 administered i.m. in Envigo mice
demonstrated less protection (70% in Jax and 60% in Envigo mice) and had a naïve mouse
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survive. Envigo mice continued to demonstrate questionable influenza immune responses and
appear more susceptible to influenza virus than Jax mice.
We found that our entire colony had been infected with an underlying respiratory illness
that was affecting our influenza challenge data. Envigo mice were more susceptible to
influenza-associated death and that mice ordered from Jax and kept away from our colony mice
worked best with our flu model. We made the decision to order mice from Jax whenever using
an influenza challenge model. We subsequently decided an investigation into the breeding
colony health status was recommended. In the meantime, all mice for influenza challenge
studies will be ordered from Jackson Labs, as mice from this vendor produced results that were
consistent with historical and published data.

Plaque Assays:
Lastly we sought to determine the infectivety of influenza viruses by plaque assay in
MDCK cells. This was done to have corresponding PFU/mL data to the LD50 data already
obtained for each influenza virus strain. Current literature suggests plaque forming units (PFUs)
are more useful and accurate in characterizing influenza strains66. MDCK.2 cells from ATCC were
used as they are susceptible to influenza type A infection. In collaboration with Dr. Tim
Borgogna (post-doc), and Julia Brown (rotating graduate student), I developed our lab’s plaque
assay protocol.
The HK68 strain used in in this data (1906 HK68, 1906 acting as a ‘lot number’ as it was
the date it was harvested and stored) had a PFU of 5*107 PFU/mL and the plaque assay results
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are shown in Figure 12B. Knowing both the PFU/ml and LD50 values enables us to calculate the
amount of PFUs that were administered (i.n.) to each mouse (Fig 12C), which will be useful for
future murine influenza challenge model development where infectious doses are measured by
PFUs and not the LD50 of the influenza strain which reduces the amount of mice used in our
influenza studies. The most recent batches of viruses, from lot 210318, have incomplete LD50
data and we are therefore unable to calculate an i.n. PFU dose, although studies are ongoing.
The i.n. dose of HK68 for each mouse challenged in this study was 125 PFU. The most
recent batch of HK68 (mouse passaged from 1906 batch), 210318 HK68 (H3N2) had 10.6*107
PFU/mL. The infectivity of H1N1 maA/Cal strain used in this study was 6.88*10 4 PFU/mL, with
each mouse in the influenza challenge study receiving 0.608 PFU. The most recent batch of
maA/Cal, 210318 maA/California (H1N1), had 9.58*104 PFU/mL. Notably, the lower PFU/ml of
maA/Cal demonstrates the lower infectivity of the H1N1 virus compared to the HK68 strains,
and corresponds to a lower LD50 as well.
Neither of the PR8s (A/PR8/1934) (egg and BALB/c mouse passaged) demonstrated
infectivity in MDCK cells. This indicates a need for further mouse adaptation of PR8 in order to
achieve infectivity or lethality.
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Figure 12. Plaque Assay of HK68 influenza viruses and comparison of influenza strain pfus and
LD50. A) Plaque assay of 210318 HK68 (H3N2) influenza A virus. B) A/HK68 influenza strain
plaque assay (HK68 influenza strain used in Chapter 3), n=2. C) Table of influenza strain
characterization of the influenza strains used in Chapter 3, including PFUs/mL, LD50 dilution, and
the IN infectious dose.
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Chapter 3: Vaccination with a combination TLR7/8 and TLR4 adjuvant liposome formulation
enhances Th1 immunity and protection from heterologous influenza challenge

I. Abstract
Influenza virus infection is a global health concern resulting in death and illness each
year, which disproportionally effects high-risk individuals. While there are several approved
vaccines for seasonal influenza, there are some limitations to consider: current vaccines provide
minimal cross protection against seasonally drifted influenza subtypes, influenza vaccine strains
change each year, requiring timely manufacture of a new vaccine. Thus, vaccines capable of
inducing a more robust and broadly protective immune response to multiple influenza subtypes
remains a critical unmet need. Adjuvants and novel delivery systems are an interesting and
promising avenue of exploration for enhancing and broadening seasonal influenza vaccine
effectiveness. Here we describe a combination TLR4 and TLR7/8 adjuvant liposome delivery
system. When combined with a detergent-split influenza vaccine, our combination adjuvant
delivery system enhanced influenza-specific humoral and cell-mediated immune responses in
mice and mini-pigs. Additionally, the combination adjuvant system demonstrates a unique and
synergistic immune response in human peripheral blood mononuclear cells (PBMCs). These
adjuvants, when delivered together in an influenza vaccine, provided protection from
heterologous (seasonally drifted) influenza challenge.
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II. Introduction
Seasonal influenza vaccines are effective when they are adequately matched to the
circulating influenza strains5,20. However, due to the time required for production of seasonal
influenza vaccines and the inherent uncertainty in predicting which influenza strains will
circulate in the human population, this remains a challenge and is a critical factor in the
effectiveness of seasonal influenza vaccines67,68. While current influenza vaccines are effective
when matched to circulating influenza strains, they fail to produce broadly neutralizing
antibodies and effective T cell responses, both shown to be important for heterosubtypic
influenza protection (cross-protection)18,69,70. Strategies to enhance influenza protection are
often utilized to protect those with increased risk for influenza infection and complications,
such as children, the elderly, pregnant persons, healthcare workers, and those with underlying
health conditions and altered immune systems11,24. These vaccination strategies, including high
antigen dose and inclusion of adjuvants, have proven more effective than the standard
seasonal influenza vaccine in high risk populations28,29,33,71–73,73–76. Therefore, an influenza
vaccine capable of inducing a robust and broadly protective immune response is a critical
unmet need.
Adjuvants are used in vaccines to enhance, prolong, and/or modulate the immune system
to maximize protection, and are a promising solution for production of cross-protective
influenza immunity67,77. The use of adjuvants could improve current seasonal influenza vaccines
by improving both durability and breadth of the immune response by promoting broadly
neutralizing antibodies and polyfunctional T cells capable of supra-seasonal protection against
multiple influenza subtypes and strains20,78,79. Pattern recognition receptor (PRR) agonists that
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stimulate the innate immune system are promising vaccine adjuvants37,38,80. One family of PRR
agonist, Toll-like receptor (TLR) agonists, have proven particularly effective as vaccine
adjuvants51,81–84. Specifically, vaccines containing adjuvants targeting TLR4 and TLR9 have been
approvedfor use in the USA to prevent human papilloma virus (HPV)85, herpes zoster61, and
hepatitis B virus42 infection34. More recently a coronavirus disease 2019 (COVID-19) vaccine
containing a TLR7/8 adjuvant was approved in India86,87.
Influenza, a single-stranded RNA virus, is recognized by TLR7/815,54, and infection results in
suppression of TLR4 expression, as TLR4 doesn’t recognize influenza associated PAMPS, and
TLR7/8 expression is induced88. Notably, TLR4 is the only TLR that signals through both TIRdomain-containing adapter-inducing interferon-β (TRIF) and myeloid differentiation primaryresponse protein 88 (MyD88)15,54. Recent studies have demonstrated TLR4 activation via the
TRIF pathway is important for DC maturation and T cell responses51,81. It was also recently
reported that type I IFNs enhance the TRIF bias of TLR4 agonists in vivo89. Since TLR7/8
stimulation results in type I IFN production16, TLR7/8 in combination with TLR4 may lead to
enhanced vaccine-induced T cell responses and humoral immunity15,53,55,90. This previous work
led us to hypothesize that a combination of TLR7/8, already known to activate antiviral
immunity, and TLR4 agonists co-encapsulated in a liposomal formulation could enhance the
durability and breadth of current influenza vaccines. The use of two novel synthetic adjuvants
co-delivered could lead to a unique immune response by simultaneously activating two similar,
but slightly different, signaling cascades resulting in a unique and enhanced innate immune
response and subsequent humoral and adaptive immunity culminating in increased influenza
protection.
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We have previously reported on a novel synthetic TLR4 ligand, CRX-601, that enhances
influenza specific immunity when co-administered with an influenza vaccine56,91. This lead
synthetic TLR4 ligand (also known as GSK1795091) was recently evaluated in a Phase I human
clinical trial for oncology58. More recently we have reported on a series of novel synthetic
oxoadenine and imidazoquinoline compounds that bind and activate TLR7/8 92–95. After further
optimization, development, and biological evaluation, compound INI-4001 has emerged as the
lead nucleolipid TLR7/8 adjuvant from this NIAID funded Adjuvant Discovery Program and is
rapidly advancing to Phase I human clinical trials.
Additive and synergistic combinations of TLR4 and TLR7/8 ligands have been previously
described, including promising combinations for improving responses to influenza vaccination
45,46,96,97.

We previously reported that co-delivery of TLR4 and imidazoquinoline-based TLR7/8

agonist compounds as a particularly promising delivery strategy56,57. The novel oxoadenine
based TLR7/8 ligand INI-4001 described herein was specifically designed for efficient
incorporation into liposomes and thus is amendable to co-delivery with synthetic TLR4 ligand,
CRX-601. Liposomes are effective vaccine delivery formulations and have demonstrated
targeted delivery to APCs, enhanced uptake and activation of desired target cells98,99. Targeted
co-delivery of the TLR7/8 and TLR4 agonists to the same cell has shown promise for enhancing
both T cell and antibody responses56. This study extends these previous findings by evaluating
innate immune activation, influenza-specific adaptive immune response, and influenza
protection using TLR4 and TLR7/8 (oxoadenine) agonists in a liposome.
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III. Methods & Materials

Synthetic Toll-like Receptor Agonists’ synthesis and formulation
CRX-601 and INI-4001 were synthesized in our laboratory as described previously. 92,100
Structure of agonists and physical characterization of formulations are presented in ST1
(supplemental table 1).

Influenza Viruses
Influenza virus strains A/Hong Kong/1/1968(H3N2) (HK68) and
A/California/07/2009(H1N1) (A/Cal) were received from ATCC and mouse adapted by serial
passage prior to use in murine challenge studies. A/California/2009/H1N1 was mouse adapted
in house as previously described65.

HEK293 TLR7 and TLR8 SEAP assays
Human TLR8 and murine TLR7 or TLR8 expressing human embryonic kidney (HEK) cells
and their corresponding Null parents were obtained from Invivogen (San Diego, CA). Human
TLR7 expressing cells were obtained from Novus (Centennial, CO). Cells were cultured according
to the manufacturer’s instructions in complete DMEM (DMEM supplemented with 10% HI FBS
(Corning), 50 U/ml penicillin, 50 mg/ml streptomycin, 50 mg/ml normocin, 2 mM L-glutamine
(Hyclone)), along with 10 mg/ml blasticidin, 100 mg/ml zeocin, and 100 mg/mL G418
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(Invivogen). HEK cells were plated at a density of 3x105 cells/well and incubated for 48 h at 37°C
with indicated concentrations of UM-3002 or INI-4001. Cell supernatants were harvested and
analyzed via the manufacturer’s instructions using the QuantiBlue kit (Invivogen). SEAP activity
was measured by reading the optical density (OD) at 620-655 nm with a microplate reader.
Data are expressed as the fold change in OD over vehicle (aqueous or blank liposomes) treated
cells.

Murine BMDCs assays
Bone marrow cells were isolated from femurs of wild type C57BL/6, TLR7 KO, TLR4/MD2
KO, MyD88 KO mice as previously described101,102 . Briefly, the cells were differentiated in
complete RPMI-1640 (RPMI supplemented with 10% FBS (Omega, Tarzana, CA), 100 U/ml
penicillin, 100 mg/ml streptomycin (Thermo Fisher Scientific), plus 20 ng/mL GM-CSF
(eBioscience, SanDiego, CA) for 8 days into BMDCs. 1x105 BMDCs/200 µL/ well were added to
serially diluted compounds and incubated at 37°C for 20 h. Culture supernatants were collected
and ELISAs were performed to determine the concentration of secreted IL-6 and TNFα (BD
Biosciences, Lajolla, CA).

Human PBMCs
Human peripheral blood mononuclear cells were obtained via on site blood draws from
healthy adult donors through a University of Montana IRB-approved protocol. PBMCs were
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separated from whole blood via density gradient separations using Histopaque 1077 (Sigma).
For PBMC-based assays, cells were washed, resuspended at the desired cell concentration in
complete RPMI (RPMI supplemented with 10% autologous human serum. Cells were plated at
5x105 cells/200 µL/well and treated with the indicated compound concentrations and
incubated for 24 h at 37°C. Supernatants were harvested from treated cells and evaluated for
TNFα (R&D Systems) and IFNα (PBL Assay Science) levels by ELISAs per the manufacturer’s
instructions. Cytokines were measured by reading the optical density (OD) at 450 nm with a
microplate reader (Molecular Devices).

Porcine PBMC assays
Porcine (Yucatan minipigs) peripheral blood was collected in sodium-heparin vacutainer
tubes (Becton Dickenson), PBMCs were separated by Ficoll gradient separation and stored at 80°C until use. Previously frozen porcine PBMCs were thawed in 37°C water bath for 10 minutes
and washed twice with complete RPMI (RPMI supplemented with 10% HI FBS (Corning), 50
U/ml penicillin, 50 mg/ml streptomycin). Cells were resuspended and plated at 5x10 5 cells/200
µL/well and treated with the indicated compound concentrations and incubated for 24 h at
37°C. Supernatants were harvested from treated cells and tested for TNFα (R&D Systems) and
IFNα (PBL Assay Science) by ELISAs per the manufacturer’s instructions. Cytokines were
measured by reading the optical density (OD) at 450 nm with a microplate reader.

In vivo experiments
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Murine studies were carried out in an OLAW and AAALAC accredited vivarium in
accordance with University of Montana’s IACUC guidelines for the care and use of laboratory
animals. Groups of 10 or 15 BALB/c mice, aged 6-8 weeks, were vaccinated intramuscularly
(i.m.) with 0.3 µg or 0.15 µg detergent-split A/Victoria influenza vaccine and indicated
concentrations of TLR7/8 and TLR4 agonists in 50 µl total volume per injection. After 14 days,
blood samples were collected for antibody analysis via submandibular bleeds and a secondary
vaccination was administered. At day 19 (5 days post-secondary vaccination), 5 mice per group
were euthanized, spleens and draining lymph nodes were harvested for the assessment of cellmediated immunity. For influenza challenge experiments the same vaccination schedule was
followed and 10 mice were anesthetized with ketamine/xylazine (i.p.) on day 42 (21 postsecondary vaccination) and challenged intranasally with 10 µl/nare of mouse-adapted A/HK/68
(H3N2) or A/Cal/2009 (H1N1) at a dose of 3LD50. Mice were observed twice daily and clinical
body scores, temperatures, and weights were recorded daily for each mouse. Criteria for
euthanasia endpoints were: 1) 30% weight loss, or 2) body temperature less than 23°C, or 3)
body temperature less than 25°C two days in a row, or 4) clinical body score of 4.
Yucatan mini pig study was performed by PAIRimmune Inc. (Laval, Qc, Canada). Animals
were housed in an animal research facility at McGill University (Montreal, Canada) and all
procedures were completed in accordance with the Canadian Council on Animal Care (CCAC)
and OLAW. Pigs were pre-screened for anti-influenza antibodies and pigs that tested positive
were excluded from the study. Immunizations (primary and boost) were administered 21 days
apart via i.m. injection using a total volume of 0.5 – 1 mL for each vaccine dose. Serum was
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collected at 14 days following each vaccination and evaluated for influenza specific humoral
immunity as described below.

Porcine HAI Assay
Chicken red blood cells (RBCs) were collected and washed in Alsever’s solution (Sigma)
(50% RBCs, 50% Alsever’s), and then washed twice with DPBS (Gibco). Serum samples were
treated with 2% Receptor Destroying Enzyme (RDE) solution (Sigma) (2% RDE stock solution +
DPBS) and incubated for 18 ± 4 h at 37°C in a water bath, then 5 volumes of sterile filtered 1.5%
sodium citrate solution (sodium citrate (Sigma) in Milli-Q water) were added and incubated for
30 ± 5 mins at 56°C in a water bath. RDE treated sera were then mixed with 10 volumes of 5%
RBC suspension (washed RBCs in DPBS) and incubated for 60 ± 5 min at 4°C, at minutes 30 and
60 samples were mixed.
An evaluation of the samples and controls were done on the same day as the HAI assay
by diluting treated samples 1:1 in DPBS and then 1:2 down the plate (50 µl/well final volume),
then 50 µl of 0.5% RBC suspension was added to each well and incubated for 45 mins at RT,
then confirmed for no hemagglutination.
Virus titration was performed by diluting virus 1:1 with DPBS, then 1:2 down the plate
(50 µL/well final volume), then 50 µL 0.5% RBC suspension was added to each well and
incubated for 45 ± 5 min at RT, then confirmed for no hemagglutination.
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The HAI assay was then performed by diluting treated samples 2:1 in DPBS, then 1:1
down the plate. 25 µL of diluted virus at 8 HA units/50 µl was added to each well (final volume
now 75 µL/well) and incubated for 45 ± 5 min at RT. Next, 50 µl 0.5% RBC suspension was
added to each well, being mindful not to touch the sides of the well (final volume now 125
µl/well, then incubated for 45 min at RT.
Plates were read by placing plates on white background, held at 45 - 90° angle until
RBCs in RBC control well (no virus) began to displace (resembling a tear drop). All wells were
checked, drawing a line over the last well where the RBCs show a tear-drop pattern, i.e. no
agglutination. The reciprocal of the last sample dilution with a tear-drop pattern is the HAI titer.

ELISA for anti-influenza antibodies
Porcine and murine serum were thawed and diluted with EIA buffer according to the
expected antibody response (between 1:10 and 1:100). Plates (96 well) were coated overnight
with 100 µl of detergent-split A/Victoria influenza vaccine at 1 µg/mL for murine and 4 µg/mL
for porcine. Following washing (KPL 10X PBSwith Tween-20, Sera Care Life Sciences Inc) and
blocking (SuperBlock, Scytek Laboratories), plates were incubated with diluted serum for 1 h
followed by either anti-mouse IgG, IgG1 or IgG2a-HRP secondary antibody (SouthernBiotech),
or anti-pig IgG-HRP secondary antibodies (Bethyl) and TMB substrate (BD). OD was measured at
450 nm.
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Splenocyte restimulation and cell-mediated immunity analysis
Spleens and draining lymph nodes (inguinal and popliteal) were harvested from
vaccinated mice 5 days after booster vaccination and cells were harvested by disruption of the
spleens and dLNs through a 100 µm filter. Red blood cells were lysed by incubation with red
blood cell lysis buffer (Sigma) for 5 min followed by washing in PBS or HBSS. Cells were plated in
a 96 well plate at 5x105 cells/well in complete RPMI1640 media and incubated with 1 µg/mL
detergent split A/Vic for 48 hr at 37°C. Supernatants were harvested and analyzed using Meso
Scale Diagnostics U-Plex platform for IL-2, IFNγ, IL-17A, IL-4, and IL-5 analytes per the
manufacturer’s instructions. Multiplex analysis was performed using a MESO QuickPlex SQ 120
instrument (Meso Scale Diagnostics) and analyzed with MSD DISCOVERY WORKBENCH
software.

Statistical Analysis
Data obtained from HEK reporter activity was expressed as fold change over media only
control and the EC50 (µM), or half-maximal effective concentration, of compounds and their
corresponding upper and lower 95% confidence intervals, were calculated by non-linear curve
fitting (GraphPad Prism 8). Data obtained from in vitro murine BMDCs were analyzed by an
ordinary two-way ANOVA, followed by a Tukey test for multiple comparisons (GraphPad Prism
8). PBMC ELISA data was analyzed by one-way ANOVA at each concentration, followed by a
Tukey test for multiple comparisons (GraphPad Prism 8); asterisks represent statistical
significance compared to blank liposomes where *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. In vivo
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antibody and cytokine data used a Kruskal-Wallis one-way ANOVA, followed by Dunn’s multiple
comparisons test (GraphPad Prism 8) to determine statistical significance; where *p ≤ 0.05, **p
≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Influenza challenge survival data was analyzed via Logrank (Mantel-Cox test) (GraphPad Prism8) to determine statistical significance and weight loss
data analysis via ordinary two-way ANOVA (GraphPad Prism 8) determined statistical
significance.

IV. Results

Figure 13. TLR4 and TLR7/8 agonist structures
Chemical structure of synthesized A.) TLR4 (CRX-601) and B.) TLR7/8 agonists. The oxoadenine
core, UM-3002, is in blue and its lipidated analog (black), is INI-4001.
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TLR Agonist Structures, TLR7/8 Binding and Activation.
The lead oxoadenine core, UM-3002, and corresponding nucleolipid, INI-4001, were
identified and optimized for human TLR7 and TLR8 activity as part of an NIAID funded Adjuvant
Discovery and Development Program (Figure 13). Core oxoadenine UM-3002 was synthesized
as previously described94 and INI-4001 was prepared using the phospholipidation we previously
developed (see Supplementary Information)92.The choline bicarbonate salt form of these
compounds can be readily formulated in 2% glycerol (aqueous formulation) or liposomes
(DOPC/cholesterol) as previously described, resulting in filter sterilizable and stable aqueous or
liposome formulations56. Agonist and liposome formulation characteristics are included in
supplemental Table 1 (ST1).
The relative potency, selectivity, and species specificity (mouse and human) of these
lead TLR7/8 ligands, in both aqueous (2% glycerol) and liposome (DOPC/cholesterol)
formulations, were measured using the human embryonic kidney 293 (HEK293) cell reporter
system and are shown in Figure 14A-D. The TLR4 receptor specificity and relative potency of
CRX-601 has been previously reported103. HEK293 cells transfected with either human or mouse
TLR7 or TLR8 receptor and an NF B responsive secreted embryonic alkaline phosphatase (SEAP)
reporter gene were incubated with serial diluted compounds for 48 hours, after which the
supernatants were collected for colorimetric determination of SEAP activity. The relative
potency and selectivity of the compounds for each receptor was determined measuring the fold
increase over vehicle control and determining the EC50 of each compound (Fig 14 A-E).
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Figure 14. TLR7/8 receptor potency and specificity in the HEK293 human and murine NF B
reporter assay. Ligand specific binding and activation is demonstrated in HEK cells and KO
murine BMDCs.
A&B) Activity of TLR7/8 and TLR4 agonists in human embryonic kidney (HEK) reporter cells
expressing mouse TLR7 or TLR8. C&D) Activity of TLR7/8 and TLR4 agonists in HEK reporter cells
expressing human TLR7 or TLR8. Cells were treated with indicated compounds formulated in
either 2% glycerol (Aq) or liposome formulation for 48 hours. Supernatants were harvested and
evaluated for SEAP activity. HEK reporter activity expressed as fold change over media only
control, displated is mean (solid line) and dotted lines represent SEM, n=3. E) The EC50 (µM) of
compounds and their corresponding upper and lower 95% confidence intervals, were calculated
by non-linear curve fitting (GraphPad Prism 8). Asterisks denote low levels of NFκB activation.
ND indicates value not defined by the statistical analysis model. F,G) Bone marrow cells were
isolated from femurs of wild type C57BL/6, TLR7 KO, TLR4/MD2 KO, MyD88 KO mice.
Compounds were serially diluted with the corresponding vehicle controls in complete RPMI.
10^5 BMDCs/200 µL/well were added to diluted compounds and incubated at 37C for 20 h.
Culture supernatants were collected and used for TNFα (pg/mL) and IL-6 (ng/mL) ELISA.
Statistical significance (n=3) determined by an ordinary two-way ANOVA, followed by a Tukey
test for multiple comparisons (GraphPad Prism 8); asterisks represent statistical significance
where ****p ≤ 0.0001.

When tested in an aqueous formulation, the non-lipidated core, UM-3002, was about 2
times more active (EC50s = UM-3002 Aq 3.069 µM, INI-4001 Aq 4.858 µM) than the
phospholipid (INI-4001) for human TLR8 activity. In contrast, INI-4001 and UM-3002
demonstrated equivalent potency for human TLR7 receptor activity (EC50 = INI-4001 Aq 1.885
µM, UM-3002 Aq 1.963 µM (Fig 14C-D). This reduction in hTLR8 activity while maintaining TLR7
responses was consistent with previous SAR studies conducted using lipidated oxoadenine and
imidazoquinoline TLR7/8 ligands93. When tested in the murine TLR7 and TLR8 reporter assay,
both compounds exhibited activity on murine TLR7, but failed to activate murine TLR8 (Fig 14AB). This finding is in agreement with previous reports indicating that murine TLR8 is not readily
activated by human TLR8 ligands104. The TLR7/8 activity was further reduced when INI-4001
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was formulated in liposomes (note that UM-3002 does not readily integrate into the liposome
bilayer and thus was only evaluated in the 2% glycerol formulation). Markedly, the INI-4001
liposome formulation was 16 times less potent than the aqueous formulation via murine TLR7
(EC50 = INI-4001 Aq 0.5822 µM, INI-4001 liposome 9.281 µM),26 times less active in human
TLR8 (EC50 = INI-4001 Aq 4.858 µM, INI-4001 liposome 128 µM), and 57 times less active in
human TLR7 (EC50s = INI-4001 Aq 1.885 µM, INI-4001 liposome 108.6 µM) (Fig 14E). These
results were expected since lower relative in vitro potency with liposome formulated TLR7/8
agonists has been reported and was often restored (or improved) upon testing for in vivo
adjuvant activity62. Blank liposomes (no TLR agonist) were inactive in this assay, revealing NFκB
activation was due to TLR7/8 binding and activation by the compounds. Similarly, UM-3002 and
INI-4001 failed to activate HEK null cells (containing the reporter gene, but lacking TLR7 or
TLR8) demonstrating specificity for the receptors (Supplemental Figure 1A-C). As expected,
CRX-601 (a TLR4 agonist) did not signal through either human or mouse TLR7 and TLR8 and no
off target NFκB activation was observed (Fig 14A-C).
To further investigate receptor specificity and explore potential additive or synergistic
effects between INI-4001 and CRX-601, these TLR ligands were evaluated in bone marrow
derived dendritic cells (BMDCs) from C57BL/6 WT and genetically modified mice as shown in
Figure 14F,G. BMDCs were derived from wild type, TLR4 KO, TLR7 KO and MyD88 KO mice and
stimulated with various combinations of INI-4001 and CRX-601 in both aqueous and liposome
formulations and evaluated for the production of pro-inflammatory cytokines IL-6 (Fig 14F) and
TNFα (Fig 14G).
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LPS, a canonical TLR4 ligand105, stimulated pro-inflammatory cytokine production in
wild-type and TLR7 KO (Fig 14F,G), but not in the TLR4 (Supplement Figure S1D,E) and MyD88
KO BMDCs (Fig 14F,G). Similarly, the synthetic TLR4 ligand CRX-601 also failed to induce
inflammatory cytokine production from the TLR4 (Supplement Figure 1D,E) or MyD88 KO
BMDCs (Fig 14F,G). The lack of cytokine production in MyD88 KO BMDCs was expected since
the cytokines evaluated are primarily induced through MyD8860. Likewise, CRX-601 liposomes
demonstrate very few in vitro activity as previously reported56. The novel TLR7/8 ligand INI4001 failed to induce cytokine expression from TLR7 KO BMDC further demonstrating the
receptor specificity of this compound (Fig 14F,G). Importantly, our aqueous and liposomal
formulations of CRX-601 and INI-4001 did not demonstrate off-target cytokine release in
murine BMDCs.
Taken together with the HEK293 data, we have demonstrated that our synthetic TLR4 and
TLR7/8 ligands bind human and murine TLR receptors, and activate signaling pathways in a
receptor-specific and dose-dependent manner.
Next, we explored if co-encapsulated or admixed CRX-601 and INI-4001 liposomes
exhibited inhibitory, additive, or synergistic effects in WT and KO BMDCs. DOPC liposomes were
prepared with single TLR agonists or co-encapsulated TLR agonists at a 10:1 ratio (INI-4001:CRX601) and tested for in vitro activity. The INI-4001 and CRX-601 combination (10:1 ratio), in both
liposome and aqueous formulations, induced significantly higher levels of both TNFα and IL-6
than either compound alone. Importantly, for both IL-6 and TNFα production, in TLR4 KO
BMDCs, there is no synergistic increase in cytokines from the combination of INI-4001 and CRX-
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601. Co-encapsulated liposomes (INI-4001:CRX-601 10:1 Liposome) exhibited similar activity to
admixed liposomes (INI-4001 lip + CRX-601 lip) in all BALB/c genotypes (Fig 14F,G).

TLR7/8 and TLR4 agonist combination elicits a unique and synergistic response in human
PBMCs

Next, we determined the cytokine profile of lead adjuvants, alone, and in combination,
in primary human and porcine peripheral blood mononuclear cells (PBMCs). As previously
mentioned, murine TLR8 does not respond to the same compounds as human or porcine TLR8
and human TLR4 is more closely related to pig than mouse106,107, making a pig animal model
more appropriate for evaluating TLR7/8 and TLR4 agonists as human adjuvants and a better
predictor of a human immune response. Porcine PBMCs were thawed from -80°C storage and
treated with single agonist liposomes as well as combination liposomes at a ratio of 10:1 of INI4001 to CRX-601. We chose to test a single ratio of the combination adjuvants to conserve
porcine PBMCs.
PBMCs were isolated from human donor whole blood and incubated with serial
dilutions of adjuvants, in liposomes, to evaluate the dose response as well as the combination
of TLR7/8 and TLR4 agonists, in varying ratios, to examine the additive or synergistic effects of
these TLR7/8 and TLR4 adjuvants. Combination liposomes were tested at three different ratios
of INI-4001 to CRX-601, 1:1, 10:1, and 100:1 and single compounds were tested at their
corresponding concentrations across the dose range, i.e. 1:1 ratio = 10 µg INI-4001: 10 µg CRX601, 1:10 ratio = 10 µg INI-4001: 1 µg CRX-601, 1:100 ratio = 10 µg INI-4001: 0.1 µg CRX-601.
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Supernatants were harvested and cytokine production was quantified by ELISA. The
combination of INI-4001 and CRX-601 was formulated using either a mixture of liposomes
containing a single agonist (admix) or liposomes that co-encapsulated both adjuvants (coencap). Pro-inflammatory cytokine TNFα and anti-viral IFNα were released in a dose-dependent
manner in response to synthetic TLR7/8 and TLR4 adjuvants, shown in Figure 15.

Figure 15. Combination of TLR7/8 and TLR4 agonists elicit a unique and additive response in
PBMCs. PBMCs were isolated from whole blood from human (n = 5) and porcine (n = 3) donors
and incubated with serially diluted indicated compounds for 24 hours. Supernatants were
harvested and A) TNFα, B) IFNα cytokines were measured via ELISAs. The concentration given on
the x-axis is the concentration of INI-4001. In the ratio studies the same amount of INI-4001 was
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tested with their corresponding concentration of CRX-601, depending upon the ratio, i.e. 1:1 –
10 µg INI-4001: 10 µg 601, 1:10 – 10 µg INI-4001: 1 µg 601, 1:100 10 µg INI-4001: 0.1 µg 601
and serial dilutions were conducted for dose response assessments. The combination of INI-4001
and CRX-601 was formulated using either a mixture of liposomes containing a singular agonist
(admix, orange) or liposomes that co-encapsulate both adjuvants (co-encap, blue). Mean and
SEM are displayed, line represents mean, n=3 for porcine and human n=5. Statistical significance
determined by one-way ANOVA for each concentration, followed by a Tukey test for multiple
comparisons (GraphPad Prism 8); asterisks represent statistical significance compared to blank
liposomes where *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Human TNFα - black asterisk * =INI-4001
lip v 10:1 admix; ## = INI-4001 lip v 1:1 admix co-encap; blue x mark = CRX-601 lip v 100:1 coencap liposomes. Human IFNa - ‡‡‡ = CRX-601 lip v 1:1 co-encap; £££ = INI-4001 lip v 100:1 coencap; §§ = CRX-601 lip v 10:1 admix; ¥¥ = INI-4001 v 10:1 admix and 10:1 co-encap and 1:1 coencap; ₮ = CRX-601 lip v 10:1 admix, 10:1 co-encap, and 100:1 admix liposomes.

Porcine cytokine production trended similarly to human PBMCs with the exception of
the adjuvant combination producing equivalent TNFα levels in minipigs to the single adjuvant
INI-4001 liposomes, as opposed to human PBMCS where the adjuvant combination liposomes
produced statistically higher TNFα levels than either adjuvant alone (Fig 15A). Additionally,
porcine IFNα levels were not statistically different between groups, whereas human IFNα
production largely resulted from INI-4001 stimulation, which was statistically decreased upon
addition of TLR4 agonist (Fig15B).
Based on the results across 5 human donors, the combination of INI-4001 and CRX-601
resulted in statistically significant higher levels of TNFα that neither adjuvant alone achieved
across the dose response range (Fig 15C). The adjuvant combinations tested exhibited additive
activity for TNFα production from human PBMCs. At agonist concentrations of 1.85, 5.56, and
16.67 µM, INI-4001 liposomes produced statistically significant less TNFα than either adjuvant
combination groups (blue and orange colored groups). At the highest agonist concentration
tested, 50 µM, the adjuvant combination 100:1 admix group produced statistically higher TNFα
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than CRX-601 liposome alone. In contrast, combinations of INI-4001 and CRX-601 do not result
in increased IFNα compared to INI-4001 (Fig 15D). The highest levels of IFNα were achieved by
INI-4001 liposomes alone. Further, at agonist concentrations of 1.86, 5.56 and 16.67 µM, INI4001 liposomes produced statistically significant higher IFNα levels compared to adjuvant
combination groups. However, at 16.67 µM 1:1 co-encapsulated liposomes produced
statistically significant higher IFNα levels than CRX-601 liposome, while INI-4001 alone
produced significantly higher levels than combination groups, demonstrating the adjuvant
combination results in a unique IFNα response.
These data alone are insufficient to determine which ratio or formulation of adjuvants
was superior, as no statistically significant differences were found between admix liposomes
versus co-encapsulated liposomal formulations at any ratio. Therefore, due to ease of
formulation, we moved forward with 10:1 ratio of INI-4001:CRX-601 for in vivo adjuvant
assessments. These data demonstrate that combined TLR7/8 and TLR4 agonists in DOPC
cholesterol liposomes results in an increased and unique immune response in human PBMCs.

Combination TLR7/8 and TLR4 agonists lead to increased humoral response and increased Th1
cytokines in an adjuvanted influenza vaccine

Next, we evaluated the effects of our adjuvants alone or in combination (admixed or coencapsulated liposomes) in a murine influenza virus vaccine study where monovalent detergent
split A/Victoria/2009(H3N2) was used as the antigen. Mice received two vaccinations, 14 days
apart, with blood taken for serum analysis on day 14 (14dp1) and day 28 (14dp2). Spleens and
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draining lymph nodes, popliteal and inguinal, were taken on day 19 (5dp2) and cells were used
for a T cell restimulation assay to measure influenza-specific T cell responses. Antigen-specific
IgG titers (IgG, IgG1, and IgG2a) from serum were evaluated via ELISA and T cell cytokine
production was measured by Meso Scale Discover (MSD) assay, a multiple secreted cytokine
assay and are shown in Figure 16.
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Figure 16. TLR7/8 and TLR4 agonist combination lead to increased influenza-specific antibody
titers and increased Th1/Th17 biased T cell response in BALB/c mice. A) Mice were immunized
i.m. 14 days apart with 0.15 µg/mouse A/Vic monovalent detergent-split influenza vaccines
adjuvanted with indicated TLR7/8, TLR4, or combination TLR7/8 + TLR4 agonists. Sera was
collected 14 days post immunizations (14dp2) and anti-influenza IgG antibodies were measured
by ELISA. B,C,D) Anti-influenza specific14dp2 antibody titers for IgG2a, IgG1, and total IgG in
response to vaccination. Individual mouse values are displayed, n=10. E,F,G) 5 days postsecondary immunization (5dp2), mice were euthanized and spleens were harvested,
disassociated and restimulated with 1 µg/mL A/Vic. The indicated cytokines were measured by
MesoScale Discovery (MSD) multiplex assay after 72 hours of stimulation. Mean and individual
values are displayed, line represents mean, n=5. Statistical significance was determined by a
Kruskal-Wallis one-way ANOVA, followed by Dunn’s multiple comparisons test (GraphPad Prism
8); asterisks represent statistical significance where *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤
0.0001.

Influenza disease in humans often correlates with low antibody responses108. Thus, we
investigated the ability of CRX-601 and INI-4001, alone and in combination, to induce influenzaspecific IgG antibodies (IgG, IgG2a, and IgG1). Both CRX-601 and INI-4001 were effective at
enhancing humoral immunity demonstrated by significantly higher anti-influenza IgG levels. The
addition of CRX-601 statistically increased influenza-specific IgG1 and total IgG antibody titers
compared to blank antigen containing liposomes (Fig 16C,D). CRX-601 enhanced both IgG1 and
IgG2a levels in comparison to blank antigen containing liposomes, suggesting a mixed Th1/Th2
response (Fig 16B,C), while the anti-influenza antibody response generated by INI-4001 was
strongly IgG2a biased suggesting a Th1 bias in regaurds to antibody production. The admixed
combination of low dose INI-4001+CRX-601 trended towards higher antibody levels than the
corresponding co-encapsulated liposomes in all IgG subtypes, reaching significance for IgG2a
(Fig 16A); however, this trend was not observed at the higher dose of adjuvant. Overall, the
adjuvant combinations induced equivalent or improved antibody titers when compared to the
single adjuvant controls.
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To examine the cell-mediated immune response in vaccinated mice, splenic T cells were
re-stimulated with A/Vic and cytokine responses were evaluated. Mice vaccinated with antigen
alone (no adjuvant) demonstrated a strong Th2 cytokine bias exemplified by statistically high IL5 cytokine levels in the culture supernatant (Fig 16F). However, INI-4001 did not change IL-5
production compared to antigen alone group, suggesting the Th2 cytokine production is a result
of antigen, rather than adjuvant activity. Of note, the addition of CRX-601 to INI-4001 in both
combination formulations, reduces the IL-5 production back to naïve levels (Fig 16F). Further
demonstrating Th1 bias, INI-4001 liposomes at 10 µg dose, as well as the low dose coencapsulated liposomes, statistically increased the levels of IFNγ (Fig 16E). The combination
adjuvants (admixed or co-encapsulated) further enhanced the Th1 bias by significantly
increasing IFN production and decreasing IL-5 in comparison to the antigen alone or single
adjuvant controls. The dual adjuvants, at their highest dose, also induce statistically significant
IL-17A production demonstrating Th17 biasing, that is not observed by either adjuvant alone
(Fig 16G). Additionally, the use of 10 µg CRX-601 (alone or in combination) as an adjuvant
induced a significant increase in IL-17 suggesting a mixed Th1/Th17 response in these groups.
What we consistently observe is that either formulation (admix or co-encapsulated) of the
combination TLR7/8 and TLR4 adjuvants induce similar antigen-specific antibody and T cell
responses.
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Co-encapsulated TLR7/8 and TLR4 liposomal adjuvants protect against heterologous influenza
virus infection via bolstered antibodies and Th1/Th17 biased T cell response

Here, we determined lead TLR7/8 and TLR4 adjuvants ability to drive an adaptive
immune response capable of influenza protection in a murine model. Influenza protection was
demonstrated by reduction in influenza infection, disease severity (as measured by weight
loss), and death. Mice were vaccinated with lead doses, combinations, and formulations of INI4001 and CRX-601, and detergent split A/Victoria/210/2009/H3N2 (A/Vic), a monovalent
seasonal influenza virus. Following the booster vaccination mice were challenged intranasally
with a drifted (heterologous) mouse adapted influenza virus, A/Hong Kong/1968/H3N2 (HK68).
To further explore the breadth of cross-protection, a second set of vaccinated mice were
challenged with a heterosubtypic mouse adapted A/California/2009/H1N1 (A/Cal) (Sup Fig).
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Figure 17. Influenza specific humoral, splenic, and lymph node T cell responses of liposomal
adjuvants.
A.) BALB/c mice were immunized twice i.m. 14 days apart with 0.15 µg detergent-split
monovalent A/Vic adjuvanted with liposomal TLR4 agonist CRX-601, TLR7/8 agonist INI-4001,
admixed INI-4001+CRX-601 liposomes, or co-encapsulated INI-4001:CRX-601 liposomes. On day
42 mice were challenged with 3LD50 of HK68 (H3N2). Body temperature, weight, and clinical
scores were assessed daily. B-D) 14 days post immunization (14dp2) mice were bled, sera
collected, and A/Vic-specific IgG2a, IgG1, and total IgG titers were measured, n=10. 5 days postsecondary immunization (5dp2), mice were euthanized and spleens and draining lymph nodes
(popliteal and inguinal) were harvested, disassociated and restimulated with 1 µg/mL A/Vic. The
indicated cytokines were measured by MesoScale Discovery (MSD) multiplex assay after 72
hours of stimulation. Mean and individual values are displayed, spleens and draining lymph
nodes n=5. Statistical significance determined by a Kruskal-Wallis one-way ANOVA, followed by
Dunn’s multiple comparisons test (GraphPad Prism 8); asterisks represent statistical significance
where *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.

As above, mice received two vaccinations, 14 days apart, with blood taken for serum
analysis on day 14 (14dp1) and day 28 (14dp2). Spleens and draining lymph nodes, popliteal
and inguinal, were taken on day 19 (5dp2) and cells were used for a T cell restimulation assay to
measure influenza-specific T cell responses. Draining lymph node T cell restimulation data (Fig
5E-G) was included to examine differences, if any, between splenic and draining lymph node T
cell activation. However, cytokine production trends appeared similar between the splenic and
lymph node T cells. Antigen-specific IgG titers (IgG, IgG1, and IgG2a) from serum were
evaluated via ELISA and T cell cytokine production was measured by Meso Scale Discover (MSD)
assay. Results are shown in Figure 17. As noted in the dose finding experiment above, antigenspecific IgG2a and total IgG antibodies were significantly increased compared to blank liposome
and antigen alone in all adjuvanted groups (Fig 17). While single adjuvant groups resulted in an
increase in antibody titers at 14dp2, the combination of TLR7/8 and TLR4 adjuvants induced the
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highest antibody titers. In fact, the dual adjuvanted liposomes produced the only statistically
significant titers compared to blank liposome and antigen in IgG and IgG2a titers (Fig 17A,D). T
cell responses in the spleen and draining lymph node also followed the general pattern
previously described with increased Th1 (IFNγ) and Th17 (IL-17A) response, and a reduced Th2
(IL-5) cytokine response in mice vaccinated with the adjuvant combination (Fig 17E-J). No
significant differences were noted between the admixed and co-encapsulated liposome
formulations. This data adds to the previous studies in demonstrating synthetic TLR7/8 and
TLR4 adjuvants, combined in liposome formulations in an influenza vaccine, lead to increased
antibody titers and enhanced Th1/Th17 biasing.
Next, we determined if our adjuvanted influenza vaccines could protect mice from
influenza challenge by performing a heterologous challenge with 3LD 50 of HK68, a genetically
drifted virus of the same subtype (H3N2). Mice received two vaccinations, 14 days apart, and
were challenged with HK68 21 days after the second vaccination. Weight loss and percent
survival are reported in Figure 18. Mice vaccinated with CRX-601 adjuvanted A/Vic were
afforded the best protection with 60% survival from the 3LD 50 A/HK/68 challenge, and was the
only group to see statistically significant protection (Fig 18A). This group also experienced
significantly less weight loss compared to naïve controls challenged with the same virus. The coencapsulated formulation of INI-4001:CRX-601 (10:1) demonstrated equivalent levels of
survival and weight loss. With respect to weight loss, the only groups that were significantly
protected compared to naïve were CRX-601 liposome (blue line and blue xmarks) on days 19
and 20, and the co-encapsulated combination group (grey dotted line, black asterisks), INI4001:CRX-601 (10:1) on days 11, 15-17, and 19-21 (Fig 18B). These data also suggest that the
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co-encapsulated formulation was superior to the admixed formulation with respect to both
survival and weight loss, although weight loss difference did not reach statistical significance.
Admix formulations demonstrated modest protection with 20% of mice surviving; all other
vaccinations resulted in 10% survival (Fig 18A). Of note, the weight loss curve for the antigen
plus liposome vehicle appear to match the antigen + adjuvant weight loss groups but this was
from a single mouse that reached nearly 30% weight loss and rapidly recovered along with the
adjuvanted groups.
Importantly, this data supports our hypothesis that targeted co-delivery of TLR7/8 and
TLR4 adjuvants in a liposome formulation can provide enhanced vaccine-mediated protection.
While survival data indicates CRX-601 provides the best protection, the antigen specific T cell
response induced by the combination of TLR7/8 and TLR4 activation is unique compared to the
TLR4 only immune response (CRX-601 treated) and could provide enhanced cell-mediated
protection that are not seen in this study due do experimental limitations.
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Figure 18. Evaluation of protection induced by TLR7/8 + TLR4 liposomal adjuvants in
heterologous influenza challenge. BALB/c mice were immunized twice i.m. 14 days apart with
0.15 µg detergent-split monovalent A/Vic adjuvanted with liposomal TLR4 agonist CRX-601,
TLR7/8 agonist INI-4001, admixed INI-4001+CRX-601 liposomes, or co-encapsulated INI4001:CRX-601 liposomes. On day 42 mice were challenged with 3LD50 HK68 (H3N2) intranasal
(10 µL/nare). Individual mouse weights were assessed daily. A) Survival data where statistical
significance was determined by Log-rank (Mantel-Cox test) (GraphPad Prism8); blue asterisk
represent statistical significance comparing blank liposome and antigen group to CRX-601
liposomes where *p ≤ 0.05. B) Percent body weight loss graph of mice challenged with HK68,
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n=10. Mean and SEM are displayed, statistical significance determined by an ordinary two-way
ANOVA (GraphPad Prism 8); black asterisks represent statistical significance of co-encapsulated
liposomes compared to naïve, blue xmark represent statistical significance of CRX-601
compared to naïve where *p ≤ 0.05, **p ≤ 0.01.

To further evaluate the extent of cross-protection, vaccinated mice were challenged
with the heterosubtypic H1N1 pandemic A/CA/09 strain, none of the vaccines elicited
significant protection (Supplement Figure S6). In the heterosubtypic influenza challenge,
modest protection from death occurred in groups vaccinated with blank liposomes and INI4001 liposomes, 20% and 10%, respectively, from mortality (Supplement Figure S6). These data
support the use of novel adjuvant combinations and delivery systems to enhance vaccine
mediated protection against heterologous (seasonally drifted) influenza viruses creating a
supraseasonal vaccine.

Co-encapsulated TLR7/8 and TLR4 adjuvants induce superior immunity in Yucatan minipigs
after influenza vaccination
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Figure 19. Co-encapsulated TLR7/8 and TLR4 adjuvants induce superior influenza vaccine
immunity in Yucatan minipigs. Yucatan mini pigs were immunized twice, i.m. 21 days apart with 1.5
µg/pig detergent-split monovalent A/Vic adjuvanted with liposomal formulations of TLR4 agonist CRX601, TLR7/8 agonist INI-4001, admixed INI-4001+CRX-601, or co-encapsulated INI-4001:CRX-601. A-C) 14
days post immunization (14dp2) pigs were bled, sera collected, and A/Vic-specific Ig2G, IgG1, and total
IgG titers were measured, n=5. D) At day 35 blood was collected via cardiac puncture and sera was used
for Hemagglutinin Inhibition Assay (HIA), n=5. Statistical significance determined by Kruskal-Wallis oneway ANOVA, followed by Dunn’s multiple comparisons test (GraphPad Prism 8); asterisks represent
statistical significance where *p ≤ 0.05.
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We, again, sought to bridge the evolutionary gap between mice and men by including lead
TLR7/8 and TLR4 agonists, alone and in combination, in liposome formulations, in an influenza
vaccine study in Yucatan minipigs. Pigs were vaccinated i.m. on days 0 and 21 with two doses
(low and high) of the liposome formulated adjuvants (with 1.5 µg A/Vic), while maintaining the
10:1 ratio of INI-4001:CRX-601 as indicated in Figure 19. Serum was collected 14 days after the
secondary vaccination and used for ELISA to determine antigen-specific IgG antibody subtype
production and hemagglutinin inhibition (Fig 19).
Interestingly, CRX-601 or INI-4001 liposomes alone significantly increased influenza-specific
IgG titers but this was not reflected in IgG2 and IgG1 isotype titers, unlike in mice (Fig 19A-C).
This is partially attributed to the high level of immunity in the antigen alone group. In IgG2 and
IgG antibody subtypes, the combination of TLR7/8 and TLR4 adjuvants, admixed or coencapsulated, lead to increased influenza-specific antibody production compared to antigen
alone. This increase was significant for IgG2 and IgG but did not reach significance for IgG1 when
using 5 pigs per group. Indeed, the adjuvant combination anti-influenza titers were also
significantly higher than the single adjuvant controls for the IgG2 isotype, consistent with the Th1
polarization noted in mice (Fig 19A). Notably, although CRX-601 liposome and the coencapsulated high dose of INI-4001 and CRX-601 produced seemingly equivalent influenzaspecific IgG antibody titers (Fig 19C), combination adjuvants resulted in increased influenzaspecific IgG2 titers compared to single adjuvant controls.
Antibody titers are used to measure antibody production, however it does not evaluate their
ability to induce effector mechanisms in response to antigen recognition 9. The hemagglutinin
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inhibition (HI) assay is a functional assay that measures the ability of serum antibodies to bind
influenza viruses and prevent red blood cell agglutination as a surrogate for virus neutralization 9.
The co-encapsulated formulation of INI-4001 (250 µg) and CRX-601 (25 µg) adjuvants in an
influenza vaccine produced higher HI titers than antigen alone and single adjuvant or admixed
formulations (Fig 19D). Of note, CRX-601 liposome produced equivalent IgG titers to the coencapsulated liposome but failed to induce measurable HI titers suggesting functional
differences in the quality of antibodies produced with these various adjuvants and combinations.
In summary, co-encapsulated liposomes with INI-4001 and CRX-601 adjuvants resulted
significantly higher influenza-specific IgG2 titers and antibody functional hemagglutinin
inhibition. This data supports our hypothesis that targeted co-delivery of both TLR7/8 and TLR4
agonists to a single cell resulted in a superior vaccine-medicated immunity to influenza
vaccination.

V. Discussion
Vaccine technology is currently in the public eye due to the recent pandemic and we have
seen that novel vaccine technology is safe and effective109,110. Several of these new vaccine
technologies may be useful to improve upon existing vaccines, particularly those targeted to
high-risk populations111. Influenza vaccines are an ideal candidate for improvement due to
variable efficacy from year to year, limited protection in vulnerable populations, and
inadequate cross-protection against drifted or shifted influenza viruses27,27. Novel adjuvants
and delivery strategies can improve upon current seasonal and pandemic influenza virus
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vaccines to induce broader protection and possibly create a universal or supraseasonal
influenza vaccine capable of protecting against multiple virus subtypes and strains 32,52,112. While
several influenza antigens currently under development have already demonstrated the ability
to produce broadly neutralizing antibodies, the addition of novel adjuvants and delivery
systems, as they have been shown to induce a Th1/Th17 biased immune response, could be the
ticket to enhancing both humoral and T cell immunity, increasing both the breadth and
duration of vaccine specific immunity56,57,113.
In the current report, we introduce a novel TLR7/8 ligand, UM-3002, and associated
nucleolipid, INI-4001, demonstrating receptor specific activity with no off target inflammatory
cytokine stimulation upon administration. As predicted, lipidation of the core TLR7/8 agonist,
UM-3002, decreased in vitro TLR7/8 potency but enabled encapsulation in a liposome for APC
targeting and co-delivery with a TLR4 ligand thus improving in vivo immunogenicity as a vaccine
adjuvant. Additionally, we provided further evidence that the combination of INI-4001 and CRX601 adjuvants lead to a unique immune response that neither compound achieved alone. The
novel co-encapsulated adjuvant combination was effective across multiple animal models both
in vitro (mouse, porcine, and human) and in vivo (mouse and porcine). This novel adjuvant
combination, when combined with a seasonal detergent-split influenza virus vaccine, improved
adaptive immunological protection against lethal heterologous influenza challenge. Here, we
can say that while the combination didn’t out-perform TLR4 agonist alone in a heterologous
influenza challenge, the combination produced a unique antigen specific Th1 T cell response,
not induced by CRX-601, that could be important in heterologous protection or for enhancing
the effectiveness of the influenza vaccine in the elderly. We hypothesize that, given the
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different signaling pathways activated by each adjuvant, dual activation of both pathways leads
to a unique immune response, not observed when each receptor was activated alone.
Mechanistic studies are in progress to further elucidate how and where in the signaling
pathway this additive effect is happening and downstream impacts on activating and biasing
adaptive immune responses.
Our data demonstrate that the use of co-encapsulated TLR4 and TLR7/8 agonists as
influenza vaccine adjuvants result in a unique immune response that could be further
developed for use in a supraseasonal influenza vaccine. There are several strategies that could
be explored to improve the breadth and durability of immune responses induced by influenza
vaccination, one of which includes using different antigens engineered to improve crossprotection114–116. Vaccination with different antigens that target the conserved stalk region of
HA or a more conserved protein (NA, nucleoprotein (NP), matrix protein 2 (M2) proton channel,
etc.) could also result in a broader neutralizing antibody response or an altered T cell response
that could produce cross-protection117–121. Determining the vaccination-induced crossprotection through in vitro functional assays or in vivo challenge studies could help define the
breadth of immunity induced by this dual-adjuvanted vaccine. Due to the unique expression
profile and functionality of TLR7/8 across species, influenza challenge in a more relevant animal
model, such as pigs, will be evaluated in future studies106. Ferrets are also an established model
for influenza vaccine research and recent studies have shown TLR7/8 agonists as adjuvants in
influenza vaccine protect against lethal infection, highlighting the relevance of this animal
model for TLR adjuvants40,122,123.
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Co-encapsulation of TLR4 and TLR7/8 agonists in a liposome resulted in superior
immunity and protection from influenza challenge compared to admixed TLR4 and TLR7/8
agonists formulated in separate liposomes. Thus, it appears that co-stimulation of TLR4 and
TLR7/8 in the same cell is important for enhanced immunity. One potential explanation for this
result may be the fact that TLR4 can signal through either the TRIF- or MyD88-dependent
signaling pathways124. Encapsulation of TLR4 ligands in a liposome has been reported to by-pass
MyD88 signaling from the cell surface and bias the signaling through TRIF in the endosome125,
the same location that TLR7/8 signaling originates126,127. Co-encapsulation of both agonists may
lead to concurrent signaling by each respective agonist in the endosome 128,129. TRIF-biased TLR4
activation leads to an increase in type 1 IFN production49,89, which subsequently leads to
increased influenza protection, as this requires Th1 immunity13,130,131. Additionally, it has been
reported that TLR7/8 activation and type 1 IFN production increase TRIF signaling, leading to a
positive feedback loop, which would further increase Th1 bias, in turn resulting in an
increasingly Th1 biased immune response53,89.
We’ve demonstrated the potential of a TLR7/8 and TLR4 adjuvant combination to improve
upon current seasonal influenza vaccines. INI-4001 and CRX-601 adjuvants added to an
influenza vaccine induce a unique antigen specific immune response and protect against
heterologous seasonally drifted H3N2 influenza challenge, indicating immediate usefulness as
an adjuvant for current seasonal influenza vaccines. The unique Th1/Th17 biased T cell
response and superior influenza-specific influenza antibody titers induced by TLR7/8 and TLR4
adjuvants, co-encapsulated in a DOPC liposome, warrants further investigation for use in
supraseasonal or prepandemic vaccines. The use of novel adjuvants, combinations and delivery
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systems is particularly appealing when targeting novel antigens for the induction of broadly
neutralizing antibodies and cross-protective memory T cells.

VI. Conclusion
Influenza continues to pose a large public health risk and new and improved influenza
vaccines that protect from a broad range of HA and NA subtypes is an unmet need. We’ve
demonstrated that using our liposomal TLR7/8 adjuvant in combination with a TLR4 adjuvant
produces a unique innate and adaptive immune response that protects against lethal
genetically drifted influenza challenge. This discovery warrants further investigation into the
potential of TLR adjuvants for use in supraseasonal vaccines.
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Chapter 4: Discussion
This post-pandemic era has brought greater understanding to the general public of the
nuances of vaccinology and the purpose and effectiveness of vaccines. As we’ve learned, the
selection of antigens and adjuvants in a vaccine can help inform and direct the immune
response to a more protective and durable one. Adjuvants are used in vaccines to enhance,
prolong, or modulate the immune system to maximize protection, and are a promising answer
to the lack of broad protection from seasonal influenza vaccintion67,77.
Influenza vaccines, while effective at reducing seasonal influenza illness,
hospitalizations, and death when accurately matched to circulating strains, fail to induce crossprotection from multiple influenza strains69. Adjuvants could be used to improve current
seasonal influenza vaccines by producing supra-seasonal vaccines that protect against multiple
influenza subtypes or used in vaccine preparedness for robust response to novel pandemic
strains3,4. Adjuvanted and high-dose seasonal influenza vaccines have demonstrated reduced
rates of hospitalization and death compared to the standard non-adjuvanted influenza vaccine
in high risk populations including the elderly11,28. Additionally, adjuvanted trivalent influenza
vaccines have already demonstrated better protection in American nursing homes when
compared to the non-adjuvanted trivalent influenza vaccine, reducing confirmed influenza
outbreaks by 22%29.
It’s estimated that nearly 75% of influenza deaths in the US are in the elderly (65 years
and older)3. Elders, especially those with comorbidities and lack of adequate health care access
have the highest risk for hospitalization and death as a result of influenza A infection11,14.
Adding to elderly and immune compromised individuals increased risk for influenza infection is
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the influenza vaccines reduced immunogenicity and declining immune function in these
populations due to their age and disease-related immune senesce132,133. Therefore, influenza
vaccination improvement is particularly important for elders and other high risk populations as
their innate immune response becomes compromised with age, or disease, resulting in reduced
antigen uptake and immunogenicity, leading to reduced vaccine effectiveness. The addition of
adjuvants could be particularly beneficial in increasing immunogenicity of the vaccine, resulting
in increased protection.
PRR agonists, such as TLR adjuvants, may be particularly helpful for those with altered
antigen processing and presentation capability. Activating a degrading pathway with antigen
and TLR agonists could ‘re-educate’ the anti-influenza response to a more appropriate antiviral
Th1 response, as opposed to the degrading pathways natural weakened response to antigen.
Reinvigorating the antiviral immune response is especially important for antigen presenting
cells, which are targeted by liposome adjuvant delivery as they are taken up by APCs and
accumulate in endosomes, as they are the link to the adaptive immune response. AS01 is a
TLR4 adjuvant system that is approved for use in vaccines and shown to result in IFNγ and
increased vaccine immunogenicity134, demonstrating TLR adjuvants relevance in antiviral
settings and immune activation in regards to immune senescence .
The use of a combination of different TLR adjuvants has demonstrated additive effects
and enhanced influenza protection45,46. TLR 7/8 adjuvants have demonstrated safety and
efficacy in multiple influenza animal models40,95,135. TLR4 agonists have shown to be protective
in homologous and heterologous influenza challenge52, and are already approved for use in
vaccines. In addition our candidate TLR 4 agonist, CRX-601, is in human clinical trials58. As
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immunogenicity is a concern in vulnerable populations, the use of multiple immunostimulators
in a vaccine to increase immune activation is an attractive solution to counteract the
immunosenescence resulting from aging and disease states. Especially considering there has
been multiple studies showing promising influenza protection from dual TLR activation,
especially the TLR7/8 and TLR4 combination45,46 which our lab has previously reported on56,57.
Liposome delivery systems, already approved for use in vaccines, demonstrate that
utilization of liposome technology for targeted APC delivery of vaccine adjuvants is safe and
effective87,120. Liposomal delivery of antigen and agonists has been shown to target APC,
increase immune activation, and initiate a TRIF-dependent TLR4 signaling pathway125,128,136,137.
Influenza vaccination improvement is particularly important for elders as their innate immune
response becomes compromised with age resulting in reduced antigen uptake and
immunogenicity, leading to reduced vaccine effectiveness132. Perhaps the combination of two
or more TLR agonists, in a delivery system that specifically targets APCs to enhance antigen
uptake (i.e. liposomes), would work to significantly improve responses in those with defective
or altered immune systems.
Additionally, the unique T cell response and Th1 bias we observed in response to dual
TLR4 and TLR7/8 activation could be utilized for high risk populations. Elderly and immune
compromised individuals are at increased risk for influenza infection, even if vaccinated, due to
the influenza vaccines reduced immunogenicity in these populations24,132. The T cell mediated
immune response has been shown to be critical in influenza cross-protection78 and the unique
affect dual TLR activation has on CD4+ T cells has yet to be fully investigated in an influenza
challenge model.
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An adaptive immune response that is altered in immune compromised individuals or the
elderly is impaired activation of CD4+ T helper cells, which are critical for influenza infection
resolution and Th2 biasing18,36,132. This is potentially another juncture where Th1 biasing
adjuvants in an influenza vaccine can come in handy to counteract the Th2 biasing. Perhaps for
the elderly, as they have reduced helper T cells that result in reduced antibody production and
function, evaluating the adaptive response, as opposed to antibody titers, would be more
helpful in evaluating the immune protection achieved in the elderly and high risk populations
and predicting the vaccine effectiveness in that population. Antibody titers are not the end-allbe-all read out for predicting vaccine effectiveness, and additional adaptive immunity
parameters should be measured in future experiments.
Our synthetic novel adjuvants are protective against genetically drifted H3N2 influenza
challenge (heterologous), but not protective in a heterosubtypic H1N1 challenge. However,
there is insufficient data to rule out that the combination of TLR7/8 and TLR4 adjuvants is
beneficial in a heterologous challenge. Namely, more investigation into the T cell mediated
immune response induced by TLR agonist combinations is called for, as well as additional
testing in ferret and porcine influenza models due to their TLRs more closely resembling human
TLRs and influenza disease symptoms107,122.
Several strategies could be used for future studies, including vaccinating with a different
antigen (chimeric HA or more conserved influenza protein)114,119, challenging with less
hetersubtypic virus as well as challenging with an influenza strain that has one envelope
subtype of the vaccinated strain in common (i.e. same NA or HA subtype). Vaccination with
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altered antigen (chimeric and recombinant) has already proven more effective than traditional
split and subunit vaccines at eliciting a strong T cell response 116.
In addition to the other strategies, evaluation of heterologous protection induced by
TLR7/8 adjuvants should be done in an animal model more analogous to humans, such as
ferrets or pigs. Perhaps there would be more of a difference between admix and coencapsulated liposomes when used in an animal model with a functional TLR8 receptor, as
murine TLR8s are thought to be relatively nonfunctional138.
Now that our lab has a lethal and characterized mouse adapted H1N1 influenza virus
(A/California), we can vaccinate with an HA derived from an H1 subtype, such as
A/Vietnam/1203/04 (H5N1) to further evaluate the influenza protection induced by our
combination TLR adjuvants. A /Vietnam would be a good choice to involve both avain (H5N1)
and swine (H1N1) derived HAs, relevant to human health, and vaccination with a subunit H1N1
has already demonstrated cross-protection (H5N1) in a mouse model112. A/Vietnam would be a
particularly good choice because avian HAs have historically been the cause of most epidemics
and pandemics and swine derived HA was the cause of the most recent influenza pandemic 139.
The current lack of heterologous protection from influenza vaccines is an ongoing global
health concern. Current influenza vaccination strategies mean we are prepared (sometimes
better than others) for seasonal outbreaks, but we are relatively unprepared for a pandemic or
epidemic of a new virulent strain as current vaccination strategies fail to induce broad crossprotection. Adjuvants, in addition to other strategies could be the solution to the dilemma of
inadequate cross-protection of seasonal influenza vaccines. TLR agonists and liposome
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formulations are already used in approved vaccines, demonstrating safety and efficacy in
vaccine settings, increasing the probability that TLR adjuvants in an influenza vaccine would
produce a safe and protective vaccine, without increasing side effects. Our data demonstrate
the unique adaptive immune response that could be further developed upon for use in a supra
seasonal or prepandemic influenza vaccine.

Chapter 5: Conclusion
While seasonal influenza vaccination has proven safe and effective, there is room for
improvement, especially concerning vaccine effectiveness in high-risk populations. Elders and
the chronically ill are the bearers of the majority of hospitalizations and mortalities, while being
least protected from influenza vaccination. Adjuvants inducing an effective and robust T cell
response and Th1 bais, like our combination synthetic TLR7/8 and TLR4 agonists, INI-4001 and
CRX-601, should be considered for further development in influenza vaccines, with special
concern for the elderly that have a Th2 bias and reduced immunogenicity.
It’s obvious that the seasonal influenza vaccine can be improved. The question is how.
Herein we advocate that targeted delivery via liposome nanoparticles, of TLR7/8 adjuvant INI4001 and TLR4 adjuvant CRX-601 results in a unique Th1 T cell response that warrents further
investigation as influenza vaccine adjuvants, for seasonal and pandemic vaccines, for the
general public, and for vulnerable populations.
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